News

Jim Hamer Elected to Unite 2 Fight Paralysis (U2FP) Board of Directors

ROCKVILLE, MD – February 16, 2021 – DP Clinical, Inc., a Contract Research Organization (CRO) located in Rockville, Maryland, announces James (Jim) Hamer, Director, Spinal Cord Injury (SCI) Programs, at DP Clinical has been elected to the Board of Directors for Unite 2 Fight Paralysis (U2FP) organization and will serve a three-year term. U2FP’s mission is to unite and empower the international spinal cord injury community to cure paralysis through advocacy, education, and support for research.

“With more than 24 years of SCI research and clinical trial experience, Jim will bring a critical perspective to the Board,” stated Devinder Poonian, President and CEO of DP Clinical.  “During his career, Jim has managed numerous acute and chronic SCI clinical trials including those with pharmaceuticals, autologous macrophages, the first in human sub-acute stem cell trials, as well as device studies.  DP Clinical started as an SCI CRO, and we look forward to witnessing one-day soon a curative therapy for this debilitating injury,” continued Ms. Poonian.

DP Clinical Supports the Maryland Tech Council’s COVID-19 Campaign

As a Rockville, Maryland-based company, DP Clinical has joined forces with other companies throughout the state to show support and unity as we work together to combat the COVID-19 pandemic. We have joined with the Maryland Tech Council to spread the word – “We come together in adversity. We put our heads down to solve complex issues. We do whatever it takes. We are truly #bettertogether!”

 

 

At DP Clinical, we continue to work tirelessly to help everyone stay safe while at the same time continuing to serve our study Sponsors, Investigator sites, patients, and DP Clinical staff.
 

DP Clinical COVID-19 Update

At DP Clinical, we are monitoring the evolving news around COVID-19 and following the best practices provided by health organizations. We want you to know that the health and well-being of our team and yours is of the utmost importance to us and is guiding our decisions during this unprecedented time. DP Clinical has implemented its business continuity procedures, and our staff is working remotely with all systems and services in place to ensure business proceeds without interruption.  We are working tirelessly to help everyone stay safe while at the same time continuing to serve you. 

Please know we are always available to you by email or phone.

This is a difficult time for all those directly and indirectly affected by COVID-19, and we will strive to make sure we are doing everything possible to minimize risk for our staff, vendors, sites, and particularly patients.

Kind regards,

The DP Clinical Team

NEWS RELEASE: DP Clinical-Supported Study Results in FDA Approval of ADMA Biologics’ ASCENIV™

ROCKVILLE, MD – September 18, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; congratulates ADMA Biologics’ on the approval of ASCENIV™ (immune globulin intravenous, human – slra 10% liquid). DP Clinical provided a full complement of CRO services for ADMA Biologics program (formerly referred to as RI-002) indicated for the treatment of Primary Humoral Immunodeficiency Disease (PIDD) in adults and adolescents. Click here to read more.

DP Clinical CEO Shares a CRO’s Perspective on Clinical Trial Evolution for Applied Clinical Trials

DP Clinical’s CEO, Devinder Poonian, was interviewed by Applied Clinical Trials for their June issue discussing a CRO’s perspective on the evolution of clinical trials. DP Clinical has been in business for more than 24 years, and Ms. Poonian shares her observations on industry changes, CRO size, and spinal cord injury trials. The article is available at http://www.appliedclinicaltrialsonline.com/clinical-trial-evolution-cro-s-perspective

DP Clinical Inaugural Member of the North American Spinal Cord Injury Consortium

DP Clinical Inaugural Member of the North American Spinal Cord Injury ConsortiumThe North American Spinal Cord Injury Consortium (NASCIC) has the mission to bring about unified achievements in research, care, and policy by fostering collaborative efforts across the spinal cord injury community. DP Clinical is an inaugural member of this important organization that brings together like-minded organizations, individuals, and groups to improve research, care, and policies impacting people living with spinal cord injury, families, and the community. Working collaboratively, the organization is structured to effectively bring out collective change through approved projects.

DP Clinical Leads Critical Aspect of SCI Research

Michele Towle, from DP Clinical, is the Chair of the American Spinal Cord Injury Association’s (ASIA) Clinical Trial Training Program Committee for International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Training. This new program will allow Sponsors and others to access formal ISNCSCI training through ASIA. Under Ms. Towle’s leadership, the team has developed processes, guidelines, policies, and training material that will be used to train staff, clinicians, and researchers involved in spinal cord injury clinical trials. The ASIA program will provide an opportunity for dissemination and training of international standards to the entire SCI community, including current and standardized material useful for both research and clinical practice.

Events

Come meet the DP Clinical team at the following conferences: